menu
    • menu

    Company profile for Geron

    NEW Drugs in Dev: 2
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Guizhou Utide Biotechnology Co., Ltd. - Specialized GMP manufacturing for next-generation GLP-1 peptide APIs.

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Imetelstat is a novel, first-in-class telomerase inhibitor exclusively owned by Geron and being developed in hematologic myeloid malignancies. Early clinical data suggest imetelstat may have disease-modifying activity throu...
    Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Imetelstat is a novel, first-in-class telomerase inhibitor exclusively owned by Geron and being developed in hematologic myeloid malignancies. Early clinical data suggest imetelstat may have disease-modifying activity through the suppression of malignant progenitor cell clone proliferation, which allows potential recovery of normal hematopoiesis. Ongoing clinical studies of imetelstat consist of IMerge™.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    GeronUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    149 Commonwealth Drive Menlo Park, CA 94025
    Telephone
    Telephone
    650-473-7700
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.geron.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/geron
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    BePharma

    Not Confirmed

    envelop Contact Supplier

    BePharma

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Geron Corp Reveals 2025 Financials And Business Updates
    Geron Corp Reveals 2025 Financials And Business Updates

    25 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/25/3244444/35501/en/Geron-Corporation-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Recent-Business-Highlights.html

    GLOBENEWSWIRE
    25 Feb 2026
    Share Share
    Geron Plans To Present At Upcoming Investor Conferences
    Geron Plans To Present At Upcoming Investor Conferences

    23 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/23/3242558/35501/en/Geron-Plans-to-Present-at-Upcoming-Investor-Conferences.html

    GLOBENEWSWIRE
    23 Feb 2026
    Share Share
    Geron Issues Inducement Grants Under Nasdaq Rule 5635(c)(4)
    Geron Issues Inducement Grants Under Nasdaq Rule 5635(c)(4)

    18 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/18/3240637/35501/en/Geron-Corporation-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    18 Feb 2026
    Share Share
    Geron To Unveil Q4 And Full Year 2025 Financials On Feb 25, 2026
    Geron To Unveil Q4 And Full Year 2025 Financials On Feb 25, 2026

    11 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/11/3236168/35501/en/Geron-Plans-to-Announce-Fourth-Quarter-and-Full-Year-2025-Financial-Results-on-February-25-2026.html

    GLOBENEWSWIRE
    11 Feb 2026
    Share Share
    Geron Corporation Provides 2026 Financial Guidance
    Geron Corporation Provides 2026 Financial Guidance

    12 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/12/3216798/35501/en/Geron-Corporation-Provides-2026-Financial-Guidance.html

    GLOBENEWSWIRE
    12 Jan 2026
    Share Share
    Geron Corp. Discloses Inducement Grants Per Nasdaq LR 5635(C)(4)
    Geron Corp. Discloses Inducement Grants Per Nasdaq LR 5635(C)(4)

    18 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/18/3208202/35501/en/Geron-Corporation-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    18 Dec 2025
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Contact Geron and get a quotation

    Geron is a supplier offers 1 products (APIs, Excipients or Intermediates).

    Find a price of Sodium DNA bulk offered by Geron

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search